14.07.2021 Drägerwerk AG & Co. KGaA  DE0005550602

DGAP-Adhoc: Drägerwerk AG & Co. KGaA: Business development in the first half year significantly above prior year despite lower earnings in the second quarter


 

DGAP-Ad-hoc: Drägerwerk AG & Co. KGaA / Key word(s): Half Year Results
Drägerwerk AG & Co. KGaA: Business development in the first half year significantly above prior year despite lower earnings in the second quarter

14-Jul-2021 / 19:29 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Ad-hoc notification in accordance with Sec. 17 of the MAR

Drägerwerk AG & Co. KGaA: Business development in the first half year significantly above prior year despite lower earnings in the second quarter

Lübeck, July 14, 2021

In the first half of 2021, Dräger's net sales and earnings were significantly above the prior-year figures. Based on preliminary business figures, the Group's net sales increased currency-adjusted by 17.3 percent (nominal 14.3 percent) to around EUR 1,633 million (6 months 2020: EUR 1,428.4 million). At around EUR 209 million, EBIT generated in the first half of the year was significantly higher than in the previous year (6 months 2020: EUR 102 million).

At around EUR 738 million order entry in the second quarter was at a similarly high level as in the first three months of the year (Q1 2021: EUR 739.8 million) due to the continuing high demand in connection with the coronavirus pandemic. Net sales were around EUR 841 million, a currency-adjusted increase of 9.0 percent (nominal: 6.7 percent) compared to the prior year's period (Q2 2020: EUR 788.4 million). EBIT came out below the level of the previous year at around EUR 80 million (Q2 2020: EUR 102 million). This was due to the lower gross margin of around 46 percent (Q2 2020: 49.2 percent) and higher functional expenses.

Due to the better than expected order development, Dräger had already raised its guidance on June 21. Following the record year 2020, management expects the Dräger Group's net sales to decline currency-adjusted by between -2.0 and -6.0 percent (nominal: -3.0 to -7.0 percent) in the current fiscal year. The EBIT margin is expected to be between 8.0 and 11.0 percent. Dräger expects pandemic-related demand to normalize in the second half of the year and does not anticipate comparable demand in the coming year.

Dräger will publish its full results for the first six months of the fiscal year on July 29, 2021.

Drägerwerk AG & Co. KGaA
Moislinger Allee 53-55
23558 Lübeck, Deutschland
www.draeger.com

Investor Relations:
Thomas Fischler
Tel. +49 451 882-2685
[email protected]

Corporate Communications:
Melanie Kamann
Tel. +49 451 882-3998
[email protected]

Disclaimer
This ad hoc report contains statements on the future development of Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to date. They were compiled to the best of the company's knowledge. Dräger does not provide any warranty nor assume any responsibility for the future developments and results described above. These are dependent on a number of factors. They entail various risks and contingencies outside of the company's influence and are based on assumptions which could prove to be incorrect. Dräger does not assume any responsibility for updating the forward-looking statements contained in this report. This does not infringe any legal stipulations on the adjustment of forecasts. Please go to Investor Relations / Definitions of financial indicators at www.draeger.com for information on alternative performance measures used.


14-Jul-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Drägerwerk AG & Co. KGaA
Moislinger Allee 53-55
23542 Lübeck
Germany
Phone: +49 (0)451 882-0
Fax: +49 (0)451 882-2080
E-mail: [email protected]
Internet: www.draeger.com
ISIN: DE0005550602, DE 000 555 063 6, DE 000 555 065 1, DE 000 555 067 7, DE 000 555 071 9
WKN: 555060, 555063 Vorzüge, 555065 Genussschein A, 555067 Genussschein K, 555071 Genussschein D
Indices: TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard), Hamburg, Hanover; Regulated Unofficial Market in Stuttgart, Tradegate Exchange
EQS News ID: 1218946

 
End of Announcement DGAP News Service

1218946  14-Jul-2021 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1218946&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 2.572,26 2.595,01 2.780,82 3.406,78 3.328,42 3.045,23 3.375,50
EBITDA1,2 240,00 147,91 193,71 521,07 421,00 55,80 315,00
EBITDA-Marge3 9,33 5,70 6,97 15,30 12,65 1,83
EBIT1,4 155,74 62,65 66,58 396,60 271,68 -88,61 166,43
EBIT-Marge5 6,05 2,41 2,39 11,64 8,16 -2,91 4,93
Jahresüberschuss1 98,50 34,90 33,79 249,89 154,27 -63,64 111,99
Netto-Marge6 3,83 1,34 1,22 7,34 4,64 -2,09 3,32
Cashflow1,7 143,34 4,09 164,42 459,98 384,89 -144,23 189,68
Ergebnis je Aktie8 4,12 1,42 1,38 10,19 7,13 -3,41 5,86
Dividende8 0,40 0,13 0,13 0,13 0,13 0,13 0,13
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: -

INVESTOR-INFORMATIONEN
©boersengefluester.de
Drägerwerk ST
WKN Kurs in € Einschätzung Börsenwert in Mio. €
555060 44,000 Kaufen 868,87
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
8,15 17,21 0,48 11,98
KBV KCV KUV EV/EBITDA
0,60 4,35 0,26 3,52
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,13 1,74 3,95 08.05.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
25.04.2024 25.07.2024 29.10.2024 07.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
1,66% 4,48% -1,57% 8,91%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Drägerwerk AG & Co. KGaA  ISIN: DE0005550602 können Sie bei EQS abrufen


Medtech , 555060 , DRW8 , XETR:DRW8